FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO124 | BLEEDING COMPLICATIONS DURING ANTICOAGULATION WITH DOACS FOR NVAF AND THEIR MOST COMMON RISK FACTORS A. delle Femine, P. Di Micco, P. Sommese, M. Di Napoli, A. Di Salvatore, M. Galdiero, A. Lobasso, R. Serpico, V. Brunelli, A. Di Fusco, C. di Gennaro | U.O.C. Medicina Interna, Osp. Santa Maria delle Grazie, Pozzuoli, Italy
32PDF: 11 -
CO064 | THROMBOTIC AND BLEEDING EVENTS IN PATIENTS WITH VASCULAR INVASION BY ADVANCED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW L. Leoni1, G. Tosti2, F.R. Ponziani2, A. Porfidia2, F. Landi2, A. Gasbarrini2, R. Pola2, F. Santopaolo2, R. Talerico2 | 1Internal Medicine Department, Vita-Salute San Raffaele University, IRCCS, Milano, Italy; 2Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
44PDF: 8 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
459PDF: 119 -
PO156 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF VTE IN PATIENTS WITH CANCER: A SURVEY AMONG CAMPANIAN INTERNAL MEDICINE WARDS E. Marrone1, C. Arturo2, F. Cannavacciulo3, D. D’Ambrosio4, F. Gallucci1, M. Amitrano3, C. Di Gennaro2, P. Morella1, A. Maffettone5 | 1UOC Medicina 3, AORN A Cardarelli, Napoli, Italy; 2UOC Medicina Generale, PO A. Rizzoli, Ischia, Italy; 3UOC Medicina Interna, AO Moscati, Avellino, Italy; 4UOC Medicina Generale, PO Piedimonte Matese ASL Caserta, Italy; 5UOC Medicina interna, PO San Luca, Vallo Della Lucania ASL Salerno, Italy
32PDF: 13 -
PO009 | THROMBOPHILIA AND ASSISTED REPRODUCTIVE TECHNOLOGY: PRELIMINARY RESULTS FROM A SINGLE CENTER RETROSPECTIVE COHORT STUDY G. Burrei2, E. Malloggi1, S. Moruzzi1, L. Delfino1, F. Pizzolo1, L. Panepinto1, F. Presa1, C. Spillere1, A. Moschella1, F. Zoccatelli1, S. Friso1, N. Martinelli1, S. Suardi1 | 1Department of Medicine, University Hospital, Verona, Italy; 2General Medicine Unit, Magalini Hospital, Villafranca di Verona, Italy
35PDF: 16 -
PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy
644PDF: 29 -
Whole exome sequencing in a family with thromboangiitis obliterans
1128PDF: 128SUPPLEMENTARY FILES: 100 -
PO12 | IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS E. Campello1, G. Furlan1, A. Boccatonda2, A. Napolitano1, C. Simion1, P. Simioni1 | 1Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 2Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy
487PDF: 113 -
PO001 | EMERGENCY DEPARTMENT MANAGEMENT OF PULMONARY EMBOLISM IN CANCER PATIENTS: PROGNOSTIC STRATIFICATION AND OUTCOMES A. Decursu1, L. Galli2, LM. Caiano2, S. Bozzato2, E. Ruggeri1, F. Paletta3, L. Vulcano1, L. Bertù1, F. Cortellaro2, W. Ageno4, MP. Donadini1|2 | 1Università degli studi dell'Insubria, Italy; 2ASST Sette Laghi, Italy; 3Università degli studi di Milano-Bicocca, Italy; 4Università degli studi di Padova, Italy
32PDF: 12 -
PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati1|2, P. Gomez-Rosas1|3, C. Ambaglio1, V. Brusegan1, O.C. Cretu1, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4|5, A. Falanga1|2, M. Marchetti1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Heidelberg, Germany; 5DOASENSE GmbH, Heidelberg, Germany
460PDF: 98 -
PO099 | CORRELATION BETWEEN DIRECT ORAL ANTICOAGULANTS PLASMA LEVELS AND BRAIN VASCULAR EVENTS L. Riva1, M. Paolucci2, S. Forlivesi2, M. Gentile2, G. Casella1, A. Zini2, R. Marcucci3 | 1UOC Cardiologia Ospedale Maggiore AUSL Bologna, Italy; 2IRCCS Istituto delle Scienze Neurologiche di Bologna UOC Neurologia e Rete Stroke metropolitana Ospedale Maggiore AUSL Bologna, Italy; 3SOD Malattie Aterotrombotiche AOU Careggi Università degli Studi di Firenze, Italy
36PDF: 12 -
OC06 | PRIMARY THROMBOPROPHYLAXIS IN ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA UNDERGOING SYSTEMIC ANTICANCER TREATMENT: A CANCER-CENTER COHORT STUDY ON CLINICAL PRACTICE AND OUTCOMES F. Haque1|2, A. Adekeye1|2, Z. Mohtashim2, K. Page1, M. Goodman1, A. Maraveyas 1|2 | 1Hull University Teaching Hospital NHS Trust, UK; 2Hull York Medical School, UK
490PDF: 108 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
447PDF: 94 -
CO042 | BLEEDING RISK IN PATIENTS RECEIVING CONCURRENT TREATMENT WITH DIRECT ORAL ANTICOAGULANTS AND CORTICOSTEROIDS: A SYSTEMATIC REVIEW M.A. Capparella1, R. Talerico2, C. Cavallaro2, M. Iorio2, F. Bossi1, A. Porfidia2, K. Abe3, M. Biglietto4, A. Chistolini4, A. Holt5, L. Lahousse6|7, R. Pola2, C. Becattini1, M.C. Vedovati1 | 1Internal, Vascular and Emergency Medicine – Stroke Unit, University of Perugia, Italy; 2Thrombosis Unit, Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy; 3Division of Gastroenterology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan; 4Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Italy; 5Department of Cardiology, Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark; 6Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; 7Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
45PDF: 18 -
CO17 | Clinical relevance of isolated anti-phosphatidylserine/ prothrombin antibody positivity A. Hoxha1, P. Žigon2,3, L. Katja2,3, S. Čučnik2,4, Ž. Rotar2,5, S. Gavasso1, P. Zerbinati1, G. Gobbo1, P. Simioni1 | 1University of Padua, Internal Medicine Unit, Thrombotic and Hemorrhagic Centre, Department of Medicine-DIMED, Padua, Italy; 2University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia; 3University of Primorska, Faculty of Mathematics, Natural Sciences and Information Technologies, Koper, Slovenia; 4University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia; 5University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
646PDF: 21 -
PO48 | Thrombotic risk evaluation and thrombophilia testing in β-thalassemia patients: a retrospective cohort analysis from a reference regional center G.M. Camarda1,2*, S. Raso1*, R. Di Maggio1, M. Vinciguerra3, A. Giangreco1, A. Inzerillo1, A. Maggio, M. Napolitano1,2 | *These authors contributed equally to this abstract; 1Hematology and Rare Diseases Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo; 2Division of Hematology Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “ProMISE”, Palermo; 3UOSD Molecular Diagnosis of Rare Blood Diseases, Azienda Ospedaliera, Ospedali Riuniti Villa Sofia, Cervello, Palermo, Italy
666PDF: 32 -
CO062 | REDUCED-DOSE DOACs IN EXTENDED TREATMENT OF CANCER-ASSOCIATED THROMBOSIS (RED-CAT): INTERIM ANALYSIS FROM A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY (COORDINATING CENTER DATA) S. Bergonzi1|2|3, A. Ghigo4, L. Carpisassi4, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|5, R. Pastorino3|5, F. Bocchi3|5, A. Porreca6|7, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Division of Internal Medicine, AOU Città della Salute e della Scienza, Università di Torino, Italy; 5Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Italy; 6Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Roma, Italy; 7Clinical and Molecular Epidemiology, IRCCS San Raffaele, Roma, Italy
38PDF: 17 -
PO94 | The use of antidepressant drugs and benzodiazepine hypnotics as an unusual risk factor for VTE G. Chiarelli, F. Strano, P. Conca, P. Rufolo, M. G. Mazzone, R. Russo, L. Jr Valletta, G. D’Errico, C. De Luca, E. Cimino, A. Tufano, M.N.D. Di Minno | Department of Clinical Medicine and Surgery, Federico II University of Naples, Italy
749PDF: 23 -
CO03 | Early discharge and home treatment of low-risk pulmonary embolism: a cohort study E. Ruggeri1, L. Vulcano1, W. Ageno2, F. Cortellaro3, M.P. Donadini3,4 | 1Scuola di Medicina, Università degli Studi dell’Insubria, Varese; 2Dipartimento di Medicina, Università degli Studi di Padova; 3Pronto Soccorso e Medicina d’Urgenza, Ospedale di Circolo, ASST Sette Laghi, Varese; 4Dipartimento di Medicina e Chirurgia, Università degli Studi dell’Insubria, Varese, Italy
675PDF: 28 -
CO086 | CLINICAL AND GENETIC CHARACTERIZATION OF A NEW FAMILY CARRYING THE “FACTOR VIII PADUA” F8 DUPLICATION E. Campello, C. Simion, F. Sartorello, D. Regazzo, C. Bulato, B. Serena, S. Toffanin, L. Spiezia, P. Simioni | Department of Medicine, University of Padova, Italy
49PDF: 16 -
CO039 | CLINICAL SAFETY AND MONITORING OF APIXABAN IN HEMODIALYSIS PATIENTS: A PROSPECTIVE STUDY S. Guglielmo1, M. Lovisotto1, E. De Bon2, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine; 2Thrombosis and Haemostasis Unit, Department of Medicine; 3Nephrology and Dialysis Unit, Azienda Ulss 6 Euganea, Cittadella and Camposampiero, Padova, Italy
45PDF: 14 -
PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933A2 AND REGN7508CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker1,2, A.P. Kithcart3, J. Kaplan3, Y-C. Cheng3, J.G. Raya3, J. Xiao3, S. Li3, K. Musgrave4, D.E. Gutstein3, G. Piazza5 | 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 5Brigham and Women’s Hospital, Boston, MA, USA
513PDF: 130 -
PO47 | Hemophilia A and antithrombin deficiency: a case of natural hemostatic rebalancing L. Torrieri, S. Ligia, E. Baldacci, R. Mormile, S. Sorella, R. Ciciani, M. Biglietto, N. Zhdanovskaya, A. Delli Paoli, A. Tirnetta, M. Lorenzon, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
637PDF: 15 -
PO077 | BALANCING BLEEDING AND THROMBOSIS: SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN PATIENTS WITH HEMOPHILIA UNDERGOING MAJOR SURGERY S. Bergonzi1|2|3, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|4, R. Pastorino3|4, F. Bocchi3|4, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Italy
28PDF: 15 -
PO57 | A NOVEL RISK ASSESSMENT MODEL FOR CANCER DETECTION WITHIN ONE YEAR AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Antoun1, J. Hansen1|3, S. Brækkan1|3, C. Langholm1, N. Eide1, V. Morelli1|3, K. Hveem2 | 1Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø; 2HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim; 3Thrombosis Research Center, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
512PDF: 105 -
PO93 | Use of DOACS in heart transplantation recipients T. Marrazzo1, A. Delle Femine1, C. Amarelli2, R. Albisinni3 | 1UOC Medicina Interna e dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 2UOSD CCH dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 3UOC CCH Generale, Ospedale Monaldi Azienda dei Colli, Napoli, Italy
751PDF: 19 -
PO18 | Does muscle mass matter? Appendicular lean mass as a determinant of anti-XA activity in elderly patientes B.M. Zanforlini1, V. Bernardi1, E. Campello2, E.M. Bicego1, C. Curreri1, A. Vaticano1, C. Sartori1, L. Manfron1, A. Perencin1, P. Rollo1, A. Baruffol1, L. Ruoso1, C. Simion2, C. Bulato2, P. Berto2, P. Simioni2, G. Sergi1 | 1Department of Medicine, Geriatrics Section, University of Padova; 2Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine DIMED, Padova University Hospital, Padova, Italy
603PDF: 18 -
CS04 | Association between elevated plasma levels of tissue plasminogen activator and occult cancer risk: a nested case-cohort analysis in 10,294 healthy subjects S. Bolognini1,2, C. Ticozzi1, P. Gomez-Rosas1,3, L. Russo1,2, Cj. Tartari1,2, F. Schieppati1,2, G. Sampietro4, L. Barcella1, M. Marchetti1,2, A. Falanga1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
703PDF: 34 -
PO105 | IMPACT OF ECOG PERFORMANCE STATUS ON CANCER-ASSOCIATED THROMBOSIS TREATED WITH DOACS: DATA FROM A MULTICENTER COHORT STUDY R. Talerico1, F. Mancinetti1, C. Sacco2, M. Mazzetti3, E. Campello4, S. Birocchi5, S. Beccatini6, A. Porfidia1, C. Lodigiani2, P. Simioni4, G.M. Podda5, I. Mastandrea2, C. Becattini6, R. Pola1, M.C. Vedovati6 | 1Thrombosis Unit, Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 2Thrombosis and Hemorrhagic Diseases Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 3Interdisciplinary Internal Medicine, Careggi University Hospital, Firenze, Italy; 4First Chair of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 5Medicine II Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milano, Milano, Italy; 6Internal, Vascular and Emergency Medicine– Stroke Unit, University of Perugia, Perugia, Italy
35PDF: 14 -
CO085 | GENE REGULATION OF THE HYPERACTIVE FIX PADUA VARIANT VIA DCAS9-KRAB TO MODULATE THROMBOPHILIA A. Benetti1, C.M. Radu1, M. Trevisan2, C. Samà1, C. Simion1, E. Campello1, P. Simioni1 | 1First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Padova, Italy; 2Department of Molecular Medicine, University of Padua, Italy
38PDF: 16 -
CO-24 | BALANCING BLEEDING AND THROMBOSIS: SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN PATIENTS WITH HEMOPHILIA UNDERGOING MAJOR SURGERY S. Bergonzi1|2|3, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|4, R. Pastorino3|4, F. Bocchi3|4, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, University of Turin, Italy
59PDF: 19 -
PO22 | LONG-TERM ANTICOAGULANT THERAPY AND REDUCTION OF OVARIAN CANCER RECURRENCE: CLINICAL EVIDENCE OF A POTENTIAL ANTITUMOUR EFFECT J. Khizroeva1, V. Bitsadze1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Khisamieva1, J. Gris1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
428PDF: 91 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
653PDF: 22 -
PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS A. Naassan, R. Fatima, M. Naassan, C. Chisholm | Lakeridge Health, R.S. McLaughlin Durham Regional Cancer Centre, Department of Oncology, Oshawa, ON, Canada
873PDF: 127 -
PO92 | Challenging management of portal vein thrombosis in a cirrhotic patient on hormone therapy after breast cancer L. Jr Valletta, C. De Luca, M. Aversano, C. Caputo, E. Cimino, P. Conca, A. Tufano, M.D. Di Minno | AOU Federico II Napoli, Italy
574PDF: 20 -
PO004 | SEX-RELATED DIFFERENCES AND PREDICTORS OF MORTALITY IN MAJOR ORTHOPEDIC SURGERY: INSIGHTS FROM THE ORTHO-START REGISTRY A. de Laurenzo1, E. Antonucci2, C. Rostagno3, D. Barcellona4, D. Colaizzo1, G. di Rienzo5, F. Gorgoglione1, G. Maccagnano6, F. Marongiu2, M. Mastroianno1, M. Marzolo7, L. Mirabella6, B. Moretti8, A.M. Moretti9, A. Ostuni6, G. Palareti2, M. Margaglione6, E. Grandone1|6 | 1Fondazione I.R.C.C.S. “Casa Sollievo della Sofferenza”, S. Giovanni R. (Foggia), Italy; 2Fondazione Arianna, Bologna, Italy; 3Department of Internal and Postoperative Medicine, Careggi University Hospital, Firenze, Italy; 4Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 5UOC Patologia Clinica-Ospedale Altamura ASL Bari, Italy; 6University of Foggia, Policlinico Riuniti Foggia, Italy; 7Angiology Unit, Ospedale di Rovigo, Rovigo, Italy; 8School of Medicine, AOU Consorziale Policlinico, University of Bari "Aldo Moro", Italy; 9President of GISeG (Italian Group for Health and Gender), Bari, Italy
28PDF: 13 -
PO61 | ACTN1-related thrombocytopenia and severe hyperhomocysteinemia: a case report A. Pozzi, G. Rosati, M. Padrini, S. Laurenti, G. Ferrari, R.M. Medici, C. Barale, I. Russo, A. Morotti | University of Turin, San Luigi Hospital, Orbassano (TO), Italy
576PDF: 17 -
CO074 | WHOLE-BLOOD COAGULATION AND PLATELET DYNAMICS IDENTIFY DIFFERENTIAL PROTHROMBOTIC STATES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK OR TNFⱭ INHIBITORS L. Spiezia, A. Giollo, L. Di Luozzo, M. Salvato, K. Khalid, R. D’Andrea, A. Benetti, C. Samà, R. Ramonda, P. Simioni | Dipartimento di Medicina, Azienda Osp. Università di Padova, Italy
52PDF: 16 -
PO33 | Whole blood hypercoagulable profiles in patients with rheumatoid arthritis L. Spiezia1, A. Giollo2, C. Samà1, A. Benetti1, L. Di Luozzo2, M. Salvato2, A. Doria2, P. Simioni1 | 1First Chair of Internal Medicine, Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padova; 2Rheumatology Unit, Department of Medicine, University Hospital of Padova, Italy
638PDF: 20 -
PO45 | KHORANA RISK SCORE AND GENOMIC PROFILING FOR PREDICTION OF VENOUS THROMBOEMBOLISM IN OVARIAN CANCER P. Santini, L. Mastrantoni, G. Anderson, F. Camarda, I. Marino, J. Preziosi, M. Buttarelli, M. Manfredelli, A. Minucci, F. Persiani, L. Giacò, T. Pasciuto, I. Conti, I. Mozzetta, F. Mancinetti, S. M. P. D’Ambrosio, M. Bigossi, C. Marchetti, V. Salutari, G. Scambia, C. Nero, R. Pola | Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy
465PDF: 116 -
PO08 | Efficacy and safety of thromboprophylaxis in hospitalized hematological patients: a monocenter retrospective study S. Cordella1,2, V. Coluccio3, M. Luppi1, M. Marietta1 | 1Department of Medical and Surgical Sciences, Section of Hematology. University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; 2Clinical and Experimental Medicine PhD Programme, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; 3Department of Hematology, Unità Sanitaria Locale di Modena, Italy
580PDF: 18 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
476PDF: 100 -
PO103 | THE EFFECT OF ALBUMIN ON SERUM CONCENTRATION OF DIRECT ORAL ANTICOAGULANTS: A CROSS-SECTIONAL STUDY A. Pannunzio1, E. Valeriani2, I.M. Palumbo1, V. Cammisotto3, S. Bartimoccia3, V. Castellani3, S. Marucci3, D. Pastori3, D. Menichelli3, P. Pignatelli3 | 1Dip. di Chirurgia generale, specialistica ed anestesiologia - Università degli studi di Roma La Sapienza, Italy; 2Dip. di Medicina Interna, Scienze Endocrino-metaboliche e Malattie Infettive - Università degli Studi di Roma La Sapienza, Italy; 3Dip. di Medicina e Scienze Cardiovascolari - Università degli Studi di Roma La Sapienza, Italy
41PDF: 12 -
PO160 | THE USE OF ANTIDEPRESSANT DRUGS AND BENZODIAZEPINE HYPNOTICS AS AN UNUSUAL RISK FACTOR FOR VTE G. Chiarelli, C. Caputo, M. Romeo, F. Strano, P. Conca, P. Rufolo, M.G. Mazzone, R. Russo, L. Valletta Jr., G. D’Errico, C. De Luca, E. Cimino, A. Tufano | DMCC. "Federico II" University of Naples, Italy
47PDF: 18 -
PO010 | D-DIMER TESTING BEYOND THROMBOSIS: A LABORATORY AUDIT OF TEST UTILIZATION, APPROPRIATENESS AND INTERPRETIVE CHALLENGES A. Mameli1, E. Casula2, E. Poma2, F. Marongiu1, D. Barcellona1 | 1Haemostasis and Thrombosis Unit; 2Laboratory Clinical Chemical Analysis and Microbiology, Azienda Ospedaliero-Universitaria (A.O.U.), Cagliari, Italy
35PDF: 13 -
CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY M. Marchetti1|2, T. Zollner1|2, O.C. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Roma, Roma, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Torino, Italy; 7Department of Medicine, University of Padua, Padova, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Roma, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
134PDF: 13 -
CO08 | The utility of urine qualitative assessment for direct oral anticoagulants in routine clinical practice F. Schieppati1,2, P. Gomez-Rosas1,3, C. Ambaglio1, V. Brusegan1, Oc. Cretu1,2, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4,5, A. Falanga1,2, M. Marchetti1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Germany; 5Germany DOASENSE GmbH, Heidelberg, Germany
753PDF: 25 -
CO049 | RANDOMIZED CONTROLLED TRIAL TO IDENTIFY THE OPTIMAL SCHEME OF HEPARIN FOR TREATMENT OF DEEP VEIN THROMBOSIS IN PREGNANCY E. Grandone1|3, E. Antonucci2, A. de Laurenzo1, L. Latino1, M. Mastroianno1, G. Tiscia1, M. Margaglione3, P. Prandoni2 | 1IRCCS Casa Sollievo della Sofferenza, S.Giovanni Rotondo, Italy; 2Fondazione Arianna, Italy; 3Università di Foggia, Italy
43PDF: 15 -
PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS S. Ramdani1, C. Séguin2 | 1Division of Hematology, Post-Graduate Medical Education Program, McGill University, Montreal; 2Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada
496PDF: 99
